Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Capmatinib

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,678Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Para IV Patent for Capmatinib (Tabrecta) Tablets
    FDA Confirms Para IV Patent for Capmatinib (Tabrecta) Tablets

    11 Jul 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-for-capmatinib-tabrecta-oral-suspension-70228.pdf

    FDA
    11 Jul 2024
    Share Share
    Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
    Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile

    27 May 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=159395&sid=2

    PHARMABIZ
    27 May 2023
    Share Share
    FDA approves capmatinib for metastatic non-small cell lung cancer
    FDA approves capmatinib for metastatic non-small cell lung cancer

    10 Aug 2022

    // US FPOOD & DRUG

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer/

    US FPOOD & DRUG
    10 Aug 2022
    Share Share
    Novartis lung cancer drug Tabrecta gets approval
    Novartis lung cancer drug Tabrecta gets approval

    22 Jun 2022

    // John Pinching PHARMATIMES

    https://www.pharmatimes.com/news/novartis_lung_cancer_drug_tabrecta_gets_approval_1450335

    John Pinching PHARMATIMES
    22 Jun 2022
    Share Share
    Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®)
    Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®)

    22 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220421006067/en

    BUSINESSWIRE
    22 Apr 2022
    Share Share
    Novartis' Tabrecta gets EMA panel backing to treat lung cancer subtype in EU
    Novartis' Tabrecta gets EMA panel backing to treat lung cancer subtype in EU

    22 Apr 2022

    // SEEKINGALPHA

    https://seekingalpha.com/news/3825805-novartis-tabrecta-gets-ema-panel-backing-for-tabrecta-to-treat-lung-cancer-subtype

    SEEKINGALPHA
    22 Apr 2022
    Share Share